Home › Funds › ORBIMED ADVISORS LLC › DYN

ORBIMED ADVISORS LLC position in DYN

DYNE THERAPEUTICS INC · Health Care

ORBIMED ADVISORS LLC reported holding 3,235,684 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$71.9M, representing 1.44% of its reported portfolio and ranking #17 among its reported holdings. ORBIMED ADVISORS LLC has disclosed DYN holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)3.24M sh
Reported value held$71.86M
Portfolio Weight1.44%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's DYN position evolved

ORBIMED ADVISORS LLC first disclosed a stake in DYN in Q1 2024 at 708,400 shares (US$20.1M). The position peaked in Q2 2026 at 3,235,684 shares, worth US$71.9M. Across 10 filings, ORBIMED ADVISORS LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 3,235,684 shares valued at US$71.9M — an increase of 317,800 shares quarter over quarter.. Notable position changes include a 73% increase in Q4 2024 (shares fell 56% over the following quarter), a 124% increase in Q3 2025 (shares rose 55% over the following quarter), a 32% increase in Q1 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 708.40K $20.11M New
Q2 2024 708.40K $25.00M Hold
Q3 2024 708.40K $25.45M Hold
Q4 2024 1.23M $28.91M Add
Q1 2025 1.01M $10.61M Reduce
Q2 2025 1.03M $9.82M Add
Q3 2025 2.31M $29.27M Add
Q4 2025 2.20M $43.07M Reduce
Q1 2026 2.92M $52.90M Add
Q2 2026 3.24M $71.86M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held DYN?

ORBIMED ADVISORS LLC has disclosed DYN holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is ORBIMED ADVISORS LLC's current position in DYN?

As of Q2 2026, ORBIMED ADVISORS LLC holds 3.24M shares of DYN (DYNE THERAPEUTICS INC), valued at $71.86M, representing 1.44% of its reported portfolio and ranking #17.

Has ORBIMED ADVISORS LLC been buying or selling DYN?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in DYN. The position peaked in Q2 2026 at 3.24M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.